# NUTSHELL Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nutshell-therapeutics

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.allonutshell.com
- Total disclosed funding: $60M
- Latest round: Series C (Sep 15, 2026)
- Investors on record: 11

## About

Established in 2013 and based in Shanghai, China, NUTSHELL Therapeutics Inc., trading as NUTSHELL Therapeutics, is a biotech company that focuses on the research and development of allosteric drug. In September 2026, NUTSHELL Therapeutics raised a Series C1 funding co-led by Trustar Capital and Decheng Capital, with participation from Fortune Capital and Guolian Group.

NUTSHELL Therapeutics has built the AlloStar™ drug discovery platform and AlloMatrix protein conformation database to identify hidden allosteric binding sites and design small-molecule drugs, while advancing a portfolio of nearly 20 internally developed programs targeting oncology, CNS, autoimmune, and metabolic diseases.

The company's revenue is generated by providing allosteric drug.

The company will use the latest funding to accelerate the iteration of the AI ??+ physical computing platform and the development of core pipelines, helping to bring high-quality new drugs empowered by AI technology to the world.

## Funding rounds

- Series C, Sep 15, 2026 — Fortune Capital, Decheng Capital, Trustar Capital, Guolian Group
- Series A, Mar 14, 2022, $40M — NLVC, Source Code Capital, Genesis Capital, MPC, Shanhai Capital, SAIC Capital
- Series A, Jun 15, 2021, $20M — NLVC, Source Code Capital, Baidu Ventures, MPC, Shanhai Capital

## Investors

- NLVC (https://capitalatlas.ai/funds/nlvc) — Series A
- Source Code Capital (https://capitalatlas.ai/funds/source-code-capital) — Series A
- Baidu Ventures (https://capitalatlas.ai/funds/baidu-ventures) — Series A
- MPC — Series A
- Shanhai Capital (https://capitalatlas.ai/funds/shanhai-capital) — Series A
- Genesis Capital — Series A
- SAIC Capital (https://capitalatlas.ai/funds/saic-capital) — Series A
- Fortune Capital — Series C
- Decheng Capital (https://capitalatlas.ai/funds/decheng-capital) — Series C
- Trustar Capital (https://capitalatlas.ai/funds/trustar-capital) — Series C
- Guolian Group (https://capitalatlas.ai/funds/guolian-group) — Series C